![Uma Sinha](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 61 200 $ in data 30/06/2026
Attualmente, Uma Sinha occupa la posizione di direttore scientifico di BridgeBio Pharma, Inc. e direttore scientifico di Eidos Therapeutics, Inc. (una filiale di BridgeBio Pharma, Inc.). La dott.ssa Sinha ha precedentemente ricoperto la posizione di responsabile scientifico della Global Blood Therapeutics, Inc., Principal presso COR Therapeutics, Inc., Senior Director-Cardiovascular presso Millennium Pharmaceuticals, Inc., Principal presso Genencor International, Inc. e Vice President & Head-Biology presso Portola Pharmaceuticals, Inc. Ha conseguito un dottorato presso l'Università della Georgia e una laurea presso il Presidency College.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 28/05/2026 | 30.000 ( 0,02% ) | 61 200 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2016 |
| BRIDGEBIO PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2016 |
| PROKIDNEY CORP. | Direttore/Membro del Consiglio | 01/07/2022 |
| Società | Posizione | Fine |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2015 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2012 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases | Corporate Officer/Principal | 01/01/2002 |
| PROKIDNEY A | Direttore/Membro del Consiglio | - |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products for acute cardiovascular diseases | Health Technology |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
University of Georgia
 University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Presidency College
 Presidency College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Social Capital Suvretta Holdings Corp. III
 Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Operates as a blank check company | Finance |
ProKidney Corp.
 ProKidney Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
